🎉 M&A multiples are live!
Check it out!

X4 Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for X4 Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

X4 Pharmaceuticals Overview

About X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.


Founded

2010

HQ

United States of America
Employees

143

Website

x4pharma.com

Financials

LTM Revenue $7.6M

LTM EBITDA n/a

EV

$11.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

X4 Pharmaceuticals Financials

X4 Pharmaceuticals has a last 12-month revenue of $7.6M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, X4 Pharmaceuticals achieved revenue of $2.6M and an EBITDA of -$27.6M.

X4 Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See X4 Pharmaceuticals valuation multiples based on analyst estimates

X4 Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $2.6M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$94.9M -$27.6M XXX XXX XXX
EBITDA Margin -Infinity% -1078% XXX XXX XXX
Net Profit -$93.9M -$101M XXX XXX XXX
Net Margin -Infinity% -3956% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

X4 Pharmaceuticals Stock Performance

As of April 15, 2025, X4 Pharmaceuticals's stock price is $0.

X4 Pharmaceuticals has current market cap of $35.6M, and EV of $11.6M.

See X4 Pharmaceuticals trading valuation data

X4 Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$11.6M $35.6M XXX XXX XXX XXX $-0.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

X4 Pharmaceuticals Valuation Multiples

As of April 15, 2025, X4 Pharmaceuticals has market cap of $35.6M and EV of $11.6M.

X4 Pharmaceuticals's trades at 1.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate X4 Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for X4 Pharmaceuticals and 10K+ public comps

X4 Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $11.6M XXX XXX XXX
EV/Revenue 4.5x XXX XXX XXX
EV/EBITDA -0.4x XXX XXX XXX
P/E -0.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get X4 Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

X4 Pharmaceuticals Valuation Multiples

X4 Pharmaceuticals's NTM/LTM revenue growth is 192%

X4 Pharmaceuticals's revenue per employee for the last fiscal year averaged $18K, while opex per employee averaged $1.0M for the same period.

Over next 12 months, X4 Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate X4 Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for X4 Pharmaceuticals and other 10K+ public comps

X4 Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -1078% XXX XXX XXX XXX
EBITDA Growth -71% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -886% XXX XXX XXX XXX
Revenue per Employee $18K XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 3193% XXX XXX XXX XXX
Opex to Revenue 5599% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

X4 Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

X4 Pharmaceuticals M&A and Investment Activity

X4 Pharmaceuticals acquired  XXX companies to date.

Last acquisition by X4 Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . X4 Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by X4 Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About X4 Pharmaceuticals

When was X4 Pharmaceuticals founded? X4 Pharmaceuticals was founded in 2010.
Where is X4 Pharmaceuticals headquartered? X4 Pharmaceuticals is headquartered in United States of America.
How many employees does X4 Pharmaceuticals have? As of today, X4 Pharmaceuticals has 143 employees.
Who is the CEO of X4 Pharmaceuticals? X4 Pharmaceuticals's CEO is Dr. Paula S. Ragan, PhD.
Is X4 Pharmaceuticals publicy listed? Yes, X4 Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of X4 Pharmaceuticals? X4 Pharmaceuticals trades under XFOR ticker.
When did X4 Pharmaceuticals go public? X4 Pharmaceuticals went public in 2017.
Who are competitors of X4 Pharmaceuticals? Similar companies to X4 Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of X4 Pharmaceuticals? X4 Pharmaceuticals's current market cap is $35.6M
What is the current revenue of X4 Pharmaceuticals? X4 Pharmaceuticals's last 12-month revenue is $7.6M.
What is the current EV/Revenue multiple of X4 Pharmaceuticals? Current revenue multiple of X4 Pharmaceuticals is 1.5x.
Is X4 Pharmaceuticals profitable? Yes, X4 Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.